{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:44:25Z","timestamp":1761327865501,"version":"build-2065373602"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031365","name":"Oslo University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031365","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Blix Family Fund for the Promotion of Medical Research"},{"DOI":"10.13039\/100020210","name":"Olav Raagholt og Gerd Meidel Raagholts stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011076","name":"Simon Fougner Hartmanns Familiefond","doi-asserted-by":"publisher","award":["101539-461587"],"award-info":[{"award-number":["101539-461587"]}],"id":[{"id":"10.13039\/501100011076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Renal dysfunction in heart failure increases mortality, limits treatment options and blunts responses to therapy. Angiotensin receptor-blocker and neprilysin inhibitors (ARNI) may preserve renal function by modulating both the renin-angiotensin-aldosterone system and the natriuretic peptide system. We investigated the renal effects of the ARNI Sacubitril\/valsartan (Sac\/Val) in rats with systolic dysfunction secondary to myocardial infarction. Male Sprague-Dawley rats underwent surgical MI induction and were randomized to six weeks of treatment with vehicle, valsartan or Sac\/Val, and compared to sham operated animals. Renal function was evaluated by creatinine clearance, mean arterial pressure (MAP) by tail-cuff measurements, and cardiac function by magnetic resonance imaging and echocardiography. Vehicle treated animals developed cardiorenal syndrome, with impaired cardiac systolic function and mild renal dysfunction. Both valsartan and Sac\/Val preserved renal function compared to vehicle (creatinine clearance\n                    <jats:italic>\n                      <jats:italic>mL\/min<\/jats:italic>\n                    <\/jats:italic>\n                    [median with interquartile range]; sham 5.4 [4.8\u20136.0], vehicle 4.5 [4.1\u20135.1], valsartan 5.1 [5.1\u20135.5], Sac\/Val 5.1 [5.0\u20135.6]; vehicle vs valsartan p\u2009=\u20090.034 and vehicle vs Sac\/Val p\u2009=\u20090.044). MAP was reduced by both treatments compared to sham and vehicle groups (MAP\n                    <jats:italic>\n                      <jats:italic>mmHg<\/jats:italic>\n                    <\/jats:italic>\n                    ; sham 131 [116\u2013138], vehicle 123 [115\u2013132], valsartan 108 [99\u2013112], Sac\/Val 111 [99\u2013119]; sham vs valsartan p\u2009&lt;\u20090.001 and sham vs Sac\/Val p\u2009=\u20090.003, vehicle vs valsartan p\u2009=\u20090.006 and vehicle vs Sac\/Val p\u2009=\u20090.041). Only Sac\/Val reduced left atrial dilatation (diameter\n                    <jats:italic>\n                      <jats:italic>mm<\/jats:italic>\n                    <\/jats:italic>\n                    ; sham 4.1 [3.7\u20134.4], vehicle 4.6 [3.8\u20135.6], valsartan 4.6 [4.1\u20135.5], Sac\/Val 3.9 [3.6\u20134.5]; vehicle vs Sac\/Val p\u2009=\u20090.047, valsartan vs Sac\/Val p\u2009=\u20090.017) despite no improvement in systolic function in either treatment group. Sac\/Val initiated in the acute post-MI phase preserved renal function to the same extent as valsartan alone and uniquely reduced left atrial dilatation, suggesting additional benefits beyond renoprotection in the setting of persistent systolic dysfunction.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0335214","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:39:38Z","timestamp":1761327578000},"page":"e0335214","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacubitril\/valsartan preserves kidney function in rats with cardiorenal syndrome after myocardial infarction"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-0929","authenticated-orcid":true,"given":"Kaja Knudsen","family":"Bergo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einar Sjaastad","family":"Nord\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e5rd Andre","family":"Bendiksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil Knut Stenersen","family":"Espe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"McGinley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Marie","family":"Hauge-Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan Iqbal","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Leh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivar","family":"Sjaastad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Cataliotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"10159","key":"pone.0335214.ref001","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"38","key":"pone.0335214.ref002","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"RA Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"pone.0335214.ref003","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2021.04.019","article-title":"New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims)","volume":"151","author":"KF Faridi","year":"2021","journal-title":"Am J Cardiol"},{"issue":"8","key":"pone.0335214.ref004","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"K Damman","year":"2007","journal-title":"J Card Fail"},{"issue":"16","key":"pone.0335214.ref005","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association","volume":"139","author":"J Rangaswami","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"pone.0335214.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)","volume":"11","author":"G Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"10","key":"pone.0335214.ref007","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"AP Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"pone.0335214.ref008","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"PA Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"pone.0335214.ref009","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ejhf.267","article-title":"Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?","volume":"17","author":"P Ruggenenti","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"pone.0335214.ref010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijcard.2014.08.032","article-title":"Natriuretic peptides and cardio-renal disease","volume":"176","author":"M Volpe","year":"2014","journal-title":"Int J Cardiol"},{"issue":"11","key":"pone.0335214.ref011","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"JJV McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"pone.0335214.ref012","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"SD Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"pone.0335214.ref013","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/eurheartj\/ehr242","article-title":"Worsening kidney function in decompensated heart failure: treat the heart, don\u2019t mind the kidney","volume":"32","author":"P Ruggenenti","year":"2011","journal-title":"Eur Heart J"},{"key":"pone.0335214.ref014","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","author":"F Spannella","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"2","key":"pone.0335214.ref015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/FJC.0000000000001379","article-title":"Renal Safety of Sacubitril\/Valsartan: A Meta-Analysis of Randomized Controlled Trials","volume":"81","author":"S Zheng","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"issue":"20","key":"pone.0335214.ref016","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction","volume":"385","author":"MA Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0335214.ref017","doi-asserted-by":"crossref","first-page":"42","DOI":"10.21037\/cdt-21-386","article-title":"Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial","volume":"12","author":"Y Dong","year":"2022","journal-title":"Cardiovasc Diagn Ther"},{"key":"pone.0335214.ref018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2020.12.037","article-title":"Comparison of the Efficacy and Safety of Sacubitril\/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction","volume":"143","author":"A Rezq","year":"2021","journal-title":"Am J Cardiol"},{"issue":"5","key":"pone.0335214.ref019","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/MCA.0000000000000932","article-title":"Effects of sacubitril\/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction","volume":"32","author":"H Wang","year":"2021","journal-title":"Coron Artery Dis"},{"issue":"4","key":"pone.0335214.ref020","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1152\/jappl.2000.89.4.1445","article-title":"Echocardiographic criteria for detection of postinfarction congestive heart failure in rats","volume":"89","author":"I Sjaastad","year":"2000","journal-title":"J Appl Physiol (1985)"},{"key":"pone.0335214.ref021","article-title":"Sacubitril\/valsartan preserves regional cardiac function following myocardial infarction in rats","author":"ES Norden","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"12","key":"pone.0335214.ref022","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ajh.2008.301","article-title":"Validation of volume-pressure recording tail-cuff blood pressure measurements","volume":"21","author":"M Feng","year":"2008","journal-title":"Am J Hypertens"},{"issue":"1","key":"pone.0335214.ref023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12968-016-0242-5","article-title":"A new automatic algorithm for quantification of myocardial infarction imaged by late gadolinium enhancement cardiovascular magnetic resonance: experimental validation and comparison to expert delineations in multi-center, multi-vendor patient data","volume":"18","author":"H Engblom","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"pone.0335214.ref024","doi-asserted-by":"crossref","first-page":"970357","DOI":"10.1155\/2015\/970357","article-title":"Validation and Development of a New Automatic Algorithm for Time-Resolved Segmentation of the Left Ventricle in Magnetic Resonance Imaging","volume":"2015","author":"J Tufvesson","year":"2015","journal-title":"Biomed Res Int"},{"issue":"3","key":"pone.0335214.ref025","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ndt\/gfm710","article-title":"Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in hypertension-induced renal damage","volume":"23","author":"M Hultstr\u00f6m","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"pone.0335214.ref026","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.HYP.26.1.101","article-title":"Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone","volume":"26","author":"A Nicoletti","year":"1995","journal-title":"Hypertension"},{"issue":"20","key":"pone.0335214.ref027","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"MA Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0335214.ref028","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/CIRCHEARTFAILURE.110.957647","article-title":"Changes in ion channel gene expression underlying heart failure-induced sinoatrial node dysfunction","volume":"4","author":"J Yanni","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"6096","key":"pone.0335214.ref029","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/324473a0","article-title":"Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney","volume":"324","author":"M Marin-Grez","year":"1986","journal-title":"Nature"},{"key":"pone.0335214.ref030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1042\/bj2910083","article-title":"Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11","volume":"291","author":"AJ Kenny","year":"1993","journal-title":"Biochem J"},{"issue":"1","key":"pone.0335214.ref031","first-page":"88","article-title":"Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions","volume":"8","author":"B Bozkurt","year":"2023","journal-title":"JACC Basic Transl Sci"},{"issue":"9","key":"pone.0335214.ref032","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00967.2011","article-title":"Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome","volume":"302","author":"S Lekawanvijit","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"pone.0335214.ref033","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00228-007-0309-1","article-title":"ANP is cleared much faster than BNP in patients with congestive heart failure","volume":"63","author":"K Kimura","year":"2007","journal-title":"Eur J Clin Pharmacol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:39:44Z","timestamp":1761327584000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335214"}},"subtitle":[],"editor":[{"given":"Sepiso K.","family":"Masenga,","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0335214","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}